Previous Close | 44.70 |
Open | 44.68 |
Bid | 44.91 x 800 |
Ask | 44.90 x 1000 |
Day's Range | 44.34 - 45.37 |
52 Week Range | 44.34 - 69.10 |
Volume | |
Avg. Volume | 16,008,464 |
Market Cap | 90.9B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.10 |
Earnings Date | Jul 26, 2024 |
Forward Dividend & Yield | 2.40 (5.37%) |
Ex-Dividend Date | Apr 04, 2024 |
1y Target Est | 54.24 |
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....
A Strategic SWOT Insight into Bristol-Myers Squibb's Financials and Future